Jubilant Pharmova jumps after reporting turnaround Q4 performance
Jubilant Pharmova rallied 4.54% to Rs 947.05 after the company reported net profit of Rs 153.60 crore in Q4 FY25 compared with net loss of Rs 58.60 crore in Q4 FY24.
Revenue from operations increased 9.7% YoY to Rs 1,915.80 crore in Q4 FY25.
The company reported pre-tax profit of Rs 206 crore in Q4 FY25 as against pre-tax loss of Rs 53.70 crore in Q4 FY24.
EBITDA jumped 23% to Rs 357 crore during the quarter compared with Rs 289 crore in Q4 FY24. EBITDA margin expanded 210 bps to 18.4% in Q4 FY25 as against 16.3% in Q4 FY24.
In Q4 FY25, radiopharmaceuticals revenue grew by 15% YoY to Rs 296 crore, while revenue from radio pharmacy increased 7% YoY to Rs 600 crore in Q4 FY25. Revenue from Allergy Immunotherapy rose 2% YoY to Rs 192 crore and CDMO sterile injectables grew by 31% YoY to Rs 340 crore during the quarter .
Contract research, development and manufacturing organisation (CRDMO) revenue stood at Rs 338 crore in Q4 FY25, up 19.86% YoY. The generics business reported revenue of Rs 157 crore in Q4 FY25, reflecting a 22% YoY decline.
On full year basis, the companys consolidated net profit surged 988.7% to Rs 839.40 crore on 8.2% increase in revenue from operations to Rs 7,192.10 crore in FY25 over FY24.
On the outlook front, in the Radiopharmaceuticals business, the company expects continued growth in Ruby-Fill installations. It remains on track to launch multiple new products in PET and SPECT imaging between FY27 and FY29. The dosing for the Phase 2 clinical trial of MIBG has been completed, and the data package is being prepared for submission to the US FDA by the second half of FY26. On the therapeutic front, over 10 new products are expected to be commercially available starting in 2029, supporting the expansion of the PET imaging industry. The proposed investment in six radiopharmacies is progressing, with commercial operations expected to begin from FY28 onwards.
In the Allergy Immunotherapy segment, the company, as the sole supplier of Venom in the US, is working to expand the market by enhancing customer awareness. Revenue continues to grow in the US allergenic extracts business, and efforts are underway to penetrate markets beyond the US.
In the CDMO Sterile Injectables segment, the capacity expansion at the Spokane, Washington facility is on schedule. Line 3 and Line 4 are expected to commence commercial production in late FY26 and FY28, respectively. Peak utilisation for Line 3 is now anticipated within three years of commercial launch, ahead of the earlier estimate of four years.
In the CRDMO business, the medium-term outlook continues to be positive. In the short term, the business is trying to diversify its customer base and for the medium term, it is adding development capabilities in addition to research and manufacturing. In the CDMO API segment, efforts are concentrated on improving capacity utilisation through CDMO projects and custom generics manufacturing.
In the Generics business, the company plans to launch six to eight products per annum in across US and non-US international markets. Export volumes to the US are being scaled up gradually and meaningfully, with increased contributions expected from contract manufacturing partners. The business aims to enhance profitability and return to growth in FY26.
In the Proprietary Novel Drugs segment, interim data from the Phase 2 trial of JBI-802 is anticipated in FY26.
Shyam. S. Bhartia, chairman Jubilant Pharmova and Hari S Bhartia, co-chairman & non-executive director, said, We are pleased to announce revenue of Rs 7,235 crore in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore, while normalised PAT grew by 112% to Rs 415 crore on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar24 to 1.1x in Mar25 on the back of voluntary debt prepayment of USD 125 million in FY25.
In Feb2025, we outlined our Vision 2030, which is to double our revenues from FY24 to FY30, improve EBITDA margins to 23% to 25% range, reduce Net debt to zero and grow Return on Capital to high teens. Our FY25 financial performance takes us one-step closer to our Vision.
During the year, the company started distributing Pylarify, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials.
The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier."
Meanwhile, the companys board recommended a final dividend of Rs 5 per share of Re 1 each for FY25. The dividend, if approved by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The company has fixed the record date as Friday, 25 July 2025, for the purpose of final dividend payment.
Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
33 minutes ago
- Time of India
Fly ash brick prices up due to raw material costs
Indore: A significant increase in raw material costs led to a price hike of 0.50 paise per piece in fly ash bricks across Indore, lifting the overall building costs for homeowners and construction companies. The surge primarily stems from the rising costs of stone crusher dust and other essential materials used in the manufacturing process. The revised cost of fly ash bricks in Indore is Rs 6.50 per piece. Now the cost of a small truckload carrying 2,000 flyash bricks will be dearer by Rs 1,000. Vijay Gandhi, a builder and member of Confederation of Real Estate Developers' Associations of India (CREDAI), Indore said, "Any jump in the input cost directly impacts the building cost. In Indore fly ash is used in around 30-40 per cent projects and red bricks are used widely in Indore due to its easy availability." The robust manufacturing base has established Indore as a significant hub for fly ash brick production in the region. According to industry data, Indore's fly ash brick manufacturing units produce approximately 20 lakh pieces daily. The majority of this production serves the local market, with most supplies being consumed within the city and a 20-kilometre radius. Abhishek Purohit, vice president, Fly Ash Brick Manufacturers Cooperative Society Ltd, said, "The association members unanimously decided in a meeting that due to the rising costs of gravel and stone crusher dust used in the production of fly ash bricks, the price per brick will be increased by 0.50 paise. These revised rates will be implemented immediately." The city hosts over 200 fly ash brick manufacturers, forming a substantial industrial segment. These units collectively require around 6,000 tonnes of fly ash per day to maintain their production levels. Industry experts suggest that this price increase could impact ongoing and planned construction projects in the area. Small-scale builders and individual homeowners might need to revise their budgets to accommodate these higher material costs. "Local manufacturers are working to maintain steady production levels while managing increased operational costs, but this has resulted in squeezed margins. Fly ash bricks offer an eco-friendly alternative to traditional clay bricks, and despite the price increase, these bricks remain an essential building material," said Gaurav Mohta, president, of the association. Fly ash manufacturers highlighted challenges related to logistics and timely transportation of fly ash to end-users.
Time of India
an hour ago
- Time of India
CM flying squad to probe MCM sanitation contract
Gurgaon: The CM flying squad has initiated an investigation into MCM's sanitation contract with Akanksha Enterprises, demanding documents such as tender details, contractor payments, and supervision records. The probe follows MCM's recent Rs 9.2 crore penalty on the contractor for inadequate service delivery. The contract, initially valid till Feb 2025, was extended to May. "A letter was sent to the MCM officials seeking details of the contract so that the CM flying squad could probe the matter. The civic body was given a week's time to probe the matter," said a ULB official privy to the matter. The contractor submitted an invoice of Rs 13.2 crore for services rendered during these three months. The representative of Akanksha Enterprises, Shishpal Rana, could not be reached despite repeated attempts by TOI. In April, the company also faced a Rs 4.3 crore penalty, during which they alleged bribery among senior MCM officials and payment delays, leading to the transfer of the then MCM commissioner. A sanitation standing committee reviewed the work of the agency between Feb 20, 2025, and May 19, 2025. A meeting was held on June 4 when the committee recommended deducting over Rs 9.17 crore from the agency's Rs 13.17 crore bill, approving only Rs 3.9 crore for payment. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo According to state govt-sanctioned estimates derived from central public health and environment engineering standards (SWM manual of CPPHEO norms, 20216) and the project's request for proposal (RFP), the agency was required to supply 1,997 personnel, 96 tractor trolleys, 468 rickshaw carts, and four earthmovers for sweeping roads in the MCM area. The urban local bodies (ULB) department stipulated that all SWM payments would be processed via the SWM monitoring portal starting Jan 2025. The committee observed a significant gap between the actual deployment figures shown on the SWM portal. It revealed personnel shortfalls of 1,315 in Feb, 1,355 in March, 1,533 in April, and 1,284 in May. Regarding equipment deployment, the committee's review showed that the agency provided only 101 rickshaw carts instead of the required 468 and merely 38 tractor trolleys against the specified 94, indicating substantial shortages in equipment provision for their work in the MCM area for three months.
Time of India
an hour ago
- Time of India
Tour operator told to refund elderly couple for cancelled tour in Covid times
Ahmedabad: A consumer commission here has ordered a tour operator to refund the full amount with interest, along with Rs 55,000 compensation, to an elderly couple whose tours to Japan and Europe could not take place due to the Covid-19 pandemic. Tired of too many ads? go ad free now The couple was reluctant to go to the UK, Ireland, and Scotland upon the operator's insistence three years later. This case involved Asha and Yogesh Doshi, residents of the Ambawadi area, who paid Rs 5.30 lakh in 2019 to Mumbai-based Neem Holidays Pvt Ltd for two tours — Japan and Europe in 2020. Due to the Covid pandemic, the tours were cancelled. When normalcy returned, they requested the same tour package, but the operator could not arrange it. Considering that people were still reeling under financial stress due to Covid, the couple did not demand their money back. In 2022, the tour operator offered them a 13-day package for Australia. They agreed and paid Rs 10,000 extra, but this did not take place. A year later, the operator offered the couple a tour to the United Kingdom. The couple refused this trip, yet their tickets were booked. They requested the company not to force them to accept this package tour and demanded their money back. As the operator did not respond, the couple sued it with the District Consumer Dispute Redressal Commission, Ahmedabad City to get the refund. The operator's lawyer appeared, but the reply was not filed. The commission said that since the money was lying with the operator, the complainants did not have any choice but to agree to the unreasonable request. However, compelling them for another tour against their wish was harassment. Tired of too many ads? go ad free now "The complainant's money has been wrongfully withheld by the opponent, and therefore the complainants are entitled to receive the full money of the package tour from the opponent," it said. The commission ordered the operator to return Rs 5.40 lakh with 8% interest, along with Rs 55,000 extra towards compensation for causing "physical harassment and mental agony" and towards the expenditure the couple incurred on litigation.
